Checkpoint Therapeutics (CKPT)
(Delayed Data from NSDQ)
$2.22 USD
-0.14 (-5.93%)
Updated Sep 24, 2024 03:59 PM ET
After-Market: $2.23 +0.01 (0.45%) 7:58 PM ET
2-Buy of 5 2
F Value B Growth A Momentum C VGM
Price, Consensus and EPS Surprise
CKPT 2.22 -0.14(-5.93%)
Will CKPT be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for CKPT based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for CKPT
What Makes Checkpoint Therapeutics (CKPT) a New Buy Stock
CKPT: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for CKPT
Buy Rating Justified by Promising Efficacy of Checkpoint’s Cosibelimab in Clinical Trials
Checkpoint Therapeutics Announces Cosibelimab Longer-Term Results in Advanced Cutaneous Squamous Cell Carcinoma Presented at ESMO Congress 2024
Checkpoint Therapeutics announces presentation of data on cosibelimab
Checkpoint Therapeutics to Present at H.C. Wainwright 26th Annual Global Investment Conference
Checkpoint Therapeutics: A Binary Bet On FDA Approval And Cosibelimab's Market Success